Insider Selling: AnaptysBio (NASDAQ:ANAB) CEO Sells $415,102.22 in Stock

AnaptysBio, Inc. (NASDAQ:ANAB) CEO Daniel Faga sold 9,202 shares of the stock in a transaction dated Wednesday, January 7th. The stock was sold at an average price of $45.11, for a total transaction of $415,102.22. Following the transaction, the chief executive officer owned 466,787 shares of the company’s stock, valued at $21,056,761.57. This represents a 1.93% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Daniel Faga also recently made the following trade(s):

• On Monday, January 5th, Daniel Faga sold 15,309 shares of AnaptysBio stock. The stock was sold at an average price of $43.26, for a total value of $662,267.34.

AnaptysBio Stock Down 3.1%

NASDAQ:ANAB traded down $1.41 during mid-day trading on Thursday, hitting $43.80. 1,747,008 shares of the stock traded hands, compared to its average volume of 768,760. AnaptysBio, Inc. has a 12-month low of $12.21 and a 12-month high of $52.47. The company has a market cap of $1.21 billion, a PE ratio of -15.53 and a beta of 0.32. The business’s 50-day moving average price is $42.31 and its 200 day moving average price is $31.22.

AnaptysBio (NASDAQ:ANAB) last announced its earnings results on Tuesday, November 4th. The biotechnology company reported $0.52 earnings per share for the quarter, beating analysts’ consensus estimates of ($1.06) by $1.58. AnaptysBio had a negative net margin of 49.94% and a negative return on equity of 1,101.24%. The business had revenue of $76.32 million for the quarter, compared to the consensus estimate of $15.83 million. Analysts anticipate that AnaptysBio, Inc. will post -6.08 earnings per share for the current fiscal year.

AnaptysBio declared that its board has initiated a stock repurchase program on Friday, November 21st that authorizes the company to buyback $100.00 million in outstanding shares. This buyback authorization authorizes the biotechnology company to purchase up to 9.6% of its stock through open market purchases. Stock buyback programs are generally an indication that the company’s board of directors believes its shares are undervalued.

Analyst Upgrades and Downgrades

ANAB has been the topic of several research analyst reports. Wedbush reissued an “outperform” rating and set a $50.00 target price on shares of AnaptysBio in a research note on Monday, November 24th. Guggenheim reissued a “buy” rating on shares of AnaptysBio in a research report on Thursday, December 18th. Wall Street Zen upgraded shares of AnaptysBio from a “buy” rating to a “strong-buy” rating in a research note on Sunday, November 16th. HC Wainwright dropped their price objective on shares of AnaptysBio from $52.00 to $51.00 and set a “buy” rating on the stock in a research note on Monday, November 24th. Finally, UBS Group assumed coverage on shares of AnaptysBio in a research note on Wednesday. They set a “buy” rating and a $70.00 target price for the company. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, AnaptysBio has a consensus rating of “Moderate Buy” and an average target price of $60.40.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Tudor Investment Corp ET AL boosted its position in shares of AnaptysBio by 47.2% during the third quarter. Tudor Investment Corp ET AL now owns 13,869 shares of the biotechnology company’s stock valued at $425,000 after buying an additional 4,450 shares during the last quarter. Jacobs Levy Equity Management Inc. increased its holdings in AnaptysBio by 2.7% during the third quarter. Jacobs Levy Equity Management Inc. now owns 378,452 shares of the biotechnology company’s stock valued at $11,588,000 after buying an additional 10,005 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in AnaptysBio in the 3rd quarter worth $315,000. Larson Financial Group LLC lifted its position in shares of AnaptysBio by 54.6% during the 3rd quarter. Larson Financial Group LLC now owns 1,340 shares of the biotechnology company’s stock valued at $41,000 after buying an additional 473 shares in the last quarter. Finally, Granahan Investment Management LLC lifted its holdings in AnaptysBio by 12.2% during the third quarter. Granahan Investment Management LLC now owns 147,773 shares of the biotechnology company’s stock valued at $4,525,000 after purchasing an additional 16,118 shares in the last quarter.

About AnaptysBio

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.